BioSpace News Archive

Nabriva Therapeutics plc, a biopharmaceutical company engaged in the commercialization and development of innovative anti-infective agents to treat serious infections, announced that it has granted a non-statutory stock option to purchase an aggregate of 100,000 ordinary shares of Nabriva Therapeutics as an inducement to Christopher Naftzger, Nabriva’s newly appointed General Counsel.

Akebia Therapeutics, Inc., a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 180,000 shares of Akebia’s common stock on September 30, 2021, as inducements material to each such employee’s entering into employment with Akebia.

Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company focused on the development and commercialization of targeted therapies for serious rare and ultra-rare diseases, reported that, in connection with the appointment of Erik Atkisson as Eiger’s General Counsel and Chief Compliance Officer, the company granted him a stock option to purchase 180,000 shares of Eiger’s common stock.

Xeris Pharmaceuticals, Inc. announced that on October 1, 2021, the Compensation Committee of Xeris’ Board of Directors granted restricted stock units for an aggregate of 28,750 shares of its common stock to 20 new employee under Xeris’ Inducement Equity Plan.

Baudax Bio, Inc. announced that the Compensation Committee of Baudax Bio’s Board of Directors approved inducement grants of stock options to purchase an aggregate of 242,688 shares of Baudax Bio’s common stock and restricted stock units covering 79,385 shares of Baudax Bio’s common stock to 22 newly-hired employees, with a grant date of September 30, 2021.

Flexion Therapeutics, Inc. announced equity inducement grants to three new employees consisting of 6,315 restricted stock units.

ImmunoGen Inc. announced that on September 30, 2021 the compensation committee of the Company’s Board of Directors granted non-qualified stock option awards to purchase an aggregate of 64,500 shares of its common stock to three employees under the ImmunoGen, Inc. Inducement Equity Incentive Plan.

Dicerna Pharmaceuticals, Inc., a leading developer of investigational ribonucleic acid interference therapeutics, announced that the Compensation Committee of the Company’s Board of Directors approved inducement grants of stock options to purchase a total of 61,350 shares of common stock and 13,650 restricted stock units to be distributed to one new employee with a grant date of Oct. 1, 2021.

We continue making great progress with COVID-19 vaccination across Canada. More than 80% of the eligible population aged 12 years and older have now been fully vaccinated.

The Food and Drug Administration’s Office of Counterterrorism and Emerging Threats has awarded a contract worth over $1.78M to Siemens Government Technologies with technology from Siemens Digital Industries.